Summary SDZ PSC 833 (PSC 833) is a non-immunosuppressive analogue of cyclosporin A and is a potent modifier of P-glycoprotein (P-gp)-mediated multidrug resistance. The present study was undertaken to evaluate whether doxorubicin (DOX) pharmacokinetic and anti-tumour activity on P388-and P388/DOX-resistant leukaemia was modified by PSC 833 pretreatment. P388-or P388/DOX-bearing mice were given PSC 833 intraperitoneally 30 min before an intravenous injection of DOX. The levels of DOX were determined by a high-performance liquid chromatography method in leukaemic cells and in normal tissues (heart, lung, liver, small intestine, kidney and spleen). In all tissues, DOX concentrations were significantly increased in mice pretreated with PSC 833. The difference was greatest in P-gp-overexpressing P388/DOX cells, the DOX area under the curve being approximately seven times greater after PSC 833 and DOX than after DOX alone. In P388 cells the difference was approximately 2.5 times, as in the majority of normal tissues. As expected DOX levels in P388 cells were higher than in P388/DOX cells in mice treated with DOX alone, whereas after PSC 833 and DOX the levels of DOX were similar in the two leukaemic lines. In spite of this PSC 833 was unable to reverse the resistance to DOX of P388/DOX leukaemia in vivo, suggesting that mechanisms other than P-gp expression are responsible for resistance.
Cyclosporin A or its non-immunosuppressive analogue PSC 833 has very good activity in reversing the resistance to several anti-cancer agents of in vitro growing cells with a multidrug resistance phenotype, i.e. those expressing the membrane P-gp (Twentyman and Bleehen, 1991; Boesch et al., 1991a; Friche et al., 1992; Keller et al., 1992; Boesch and Loor, 1994) .
Preclinical information on the combination of cyclosporins with anti-cancer drugs in vivo is limited. Recent reports indicate that cyclosporin A or PSC 833 (Gonzalez et al., 1995) pretreatment significantly increases the retention of DOX in mouse normal tissues such as liver, kidney, intestine, adrenals and heart. The changes in DOX distribution may be related to the cyclosporins' ability to inhibit P-gp, thus reducing the rate of drug transport out of the cells. P-gp is not only expressed in resistant tumour cells, but also in many normal tissues (Fojo et al., 1987; Thiebaut et al., 1987; Croop et al., 1989; Endicott and Ling, 1989;  Ford and Hait, 1990) where it probably helps defend against potentially toxic xenobiotics.
Cyclosporin A or PSC 833 were reported to increase the toxicity of DOX in normal mice, suggesting that DOX doses should be reduced when used with either of these drugs Gonzalez et al., 1995) . Recent clinical data indicate that, although PSC 833 alone does not cause any evident toxicity, when combined with DOX it strongly enhances its toxicity, so the DOX dose must be reduced (Erlichman et al., 1993; Giaccone et al., 1994) . However, reducing the DOX dose also lowers the chances of therapeutic success.
It is reasonable to assume that, if the cyclosporin-induced increase in tissue retention of DOX is similar in normal and neoplastic tissues, the combination of DOX 1985) . P388 and its subline resistant to DOX (P388/DOX) were kindly provided by Dr Pesenti, Pharmacia-Farmitalia-Carlo Erba, Milan. The parental line and the resistant subline were passaged weekly through DBA and BDFI mice. P388 and P388/DOX cell lines grew at the same rate, both producing ascites; by transplanting the same number of cells the survival was similar for both tumour cell lines.
For evaluation of anti-tumour activity one million leukaemia cells were inoculated intraperitoneally (i.p.) and mice were treated on day 1 after tumour transplant. DOX was injected intravenously (i.v.) with different schedules and PSC 833 was given i.p. 30 min before DOX. The time interval between the administration of PSC 833 and DOX was selected on the basis of our previous studies Gonzalez et al., 1995 Table I . Table  I . In all tissues DOX levels were higher (P <0.01) in mice also given PSC 833; DOX concentrations in P388/DOX cells after Table I . Figure 3 ). P388/DOX cells presented overexpression of the mdrl gene either in vitro or in vivo. In P388 cells mdr expression was clearly much less than in the resistant subline. Nevertheless in the sensitive P388 it was also detectable both in vitro and in vivo. In P388 cells growing in vivo, which are more relevant for our studies, the expression of mdrl appeared to be higher than in P388 cells growing in vitro. 
Discussion
Studies in normal mice showed that DOX distribution was greatly influenced by pretreatment with either cyclosporin A or PSC 833 (Gonzalez et al., 1995) . The present study in P388-or P388/DOX-bearing mice confirms and extends these findings. The 2-3 times increase in DOX AUC was similar to that described in liver, kidney, intestine and heart of normal mice. In lungs, which were not examined in previous studies, pretreatment with PSC 833 also increased DOX retention with DOX AUC approximately double that after DOX alone. These changes in DOX distribution induced by PSC 833 treatment may well be due to the inhibition of P-gp, which appears to be expressed in these tissues (Kaye, 1993; Gottesman, 1993) . However other, not yet identified, transport membrane proteins may be inhibited by PSC 833. The lack of any real difference in DOX plasma levels in mice receiving DOX alone or in combination with PSC 833, and the findings of previous detailed studies on the urinary and faecal elimination of DOX and its metabolites (Gonzalez et al., 1995) suggest that PSC 833 mainly affects tissue distribution.
The main aims of this study were to investigate whether PSC 833 increased the DOX AUC in tumour cells, particularly those overexpressing P-gp, and whether the increase was greater than in normal tissues of the same mice. The finding that PSC 833 raises DOX intracellular concentrations much more in the P388/DOX tumour than in other tissues is the first evidence that a selectivity of action of a reversing agent can be obtained in vivo towards mdr cancer cells. After administration of the combination of PSC 833 and DOX the concentrations of DOX in P388/DOX cells were even higher than in P388 cells after DOX alone. Therefore it was expected that PSC 833 in combination with DOX might reverse the resistance of P388/DOX leukaemia. Instead, the combination did not significantly improve. The most likely explanation is that the resistance of P388/DOX to DOX is not only due to overexpression of P-gp, with consequent lower drug retention, but to other mechanisms as well. Resistance to DOX might be due to mutation of topoisomerase II, which can become less susceptible to inhibitors of the enzyme (Capranico et al., 1986; Sikic, 1993; Isaacs et al., 1995) .
Possibly, therefore, P388/DOX leukaemia is not the most suitable experimental model for investigating whether a reversing agent restores sensitivity to DOX or other chemotherapeutic agents.
However, P388/DOX leukaemia is one of the most widely used models for studies on drugs that counteract mdr (Grandi et al., 1987; Radel et al., 1988; Boesch et al., 1991b; Tomida, 1995). Boesch et al. (1991b) reported that PSC 833 significantly prolonged the median survival time in P388/DOX leukaemia. They specified the source of the leukaemia, which was the same as ours, thus excluding the possibility that the differences were due to differences in the two tumour lines. The routes and dosage schedules, however, were different. They gave PSC 833 orally at doses of 25 or 50 mg kg-' and DOX i.p. at the dose of 2 mg kg-' on days 0, 4 and 8 after tumour implant, whereas we gave PSC 833 i.p. (12.5 mg kg-') 30 min before DOX i.v. (2.5, 5, 10 mg kg-'). To clarify this point we also assessed the effect of oral PSC 833 given by the same oral dosage schedules as Boesch et al., administering DOX i.v. at doses of 1.99, 2.51, 3.15 and 4 mg kg-' (data not shown). However, the combination had no activity, T/C being 115 compared with 100 for controls receiving either PSC 833 or the vehicle. Possibly therefore the better results reported by Boesch et al. are due to the fact that they gave DOX by the i.p. route. Since they did not report the effects of DOX alone at doses higher than 2 mg kg-1 we cannot establish whether PSC 833 improved the therapeutic index in their conditions. We did not repeat the experiments giving DOX i.p. because by this route DOX causes chemical peritonitis. In our opinion the strong inflammation that is certainly associated with the i.p. injection of DOX makes it difficult to interpret the therapeutic outcome in i.p. transplanted leukaemias. In addition, results in mice given DOX i.p. are of scant value as the i.p. route cannot be used in cancer patients on account of the irritation caused by the drug.
The finding that PSC 833 can greatly increase DOX concentrations in a DOX-resistant tumour indicates that PSC 833 is a potentially effective mdr reversing agent for tumours whose mechanism of resistance is entirely related to P-gp expression. However most advanced human drug-resistant tumours, probably like the mouse P388/DOX leukaemia, do not appear to have one single mechanism of resistance, but a variety of different ones, including transport mechanisms, alterations of the molecular target (e.g. mutations of DNA topoisomerases in the case of anthracyclines) and also more general mechanisms related to the triggering of the process of cell death after drug-induced perturbations (e.g. increased expression of the bcl-II gene). The more advanced and pretreated the tumour the greater are the chances it will contain cellular clones with multiple and complex resistance mechanisms. It is therefore not surprising that the results so far with reversing agents in extensively pretreated cancer patients highly resistant to chemotherapy have been disappointing (Rodenburg et al., 1991; Raderer and Scheithauer, 1993; D'Incalci, 1995) .
An additional finding of the present study is that when PSC 833 was combined with DOX in the sensitive P388 leukaemia there was marked potentiation of anti-tumour activity, with an increase in survival time compared with that of DOX alone. This unexpected finding prompted us to verify whether P388 cells were expressing the mdr gene. Northern blot analysis showed that mdr gene mRNA was detectable in P388 cells, although at a very low level compared with P388/ DOX cells. The expression of the mdr gene explains why PSC 833 enhances DOX distribution in these cells. The enhancement, however, was similar or slightly higher than that found in the normal tissues, which also express the mdr gene. However in terms of the therapeutic index the superiority of the combination of DOX and PSC 833 over DOX alone in P388-leukaemia bearing mice appears questionable. In fact, for example, survival time of mice treated with 5 mg kg-' DOX associated with PSC 833 appeared similar to that of mice given 10 mg kg-' DOX alone. In conclusion the results shown in the present study do not support the clinical use of PSC 833 combined with DOX for resistant tumours. It is still open to question whether the combination of DOX, at a reduced dose, with PSC 833 can be advantageous over a high dose of DOX alone for some moderately resistant tumours whose resistance mechanism is supposedly only linked to mdr expression.
